Truist Financial’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Truist Financial’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-150,000	Closed	-$843K	–	2898
2021 Q4	$843K	Sell	150,000 -5,000	-3%	-$31.8K	﹤0.01%	1729
2021 Q3	$992K	Sell	155,000 -65	-0%	-$418	﹤0.01%	1614
2021 Q2	$1.31M	Buy	155,065 +36,065	+30%	+$291K	﹤0.01%	1496
2021 Q1	$1.25M	Sell	119,000 -21,000	-15%	-$296K	﹤0.01%	1453
2020 Q4	$2.37M	Buy	140,000 +16,000	+13%	+$240K	﹤0.01%	1100
2020 Q3	$1.59M	Buy	124,000 +10,000	+9%	+$126K	﹤0.01%	1164
2020 Q2	$1.61M	Buy	114,000 +30,000	+36%	+$379K	﹤0.01%	1121
2020 Q1	$773K	Buy	84,000 +32,000	+62%	+$412K	﹤0.01%	1367
2019 Q4	$775K	Buy	+52,000	New	+$463K	﹤0.01%	1578

Other funds holding PRVB

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Truist Financial's PRVB Position: Q1 2022 in Review

Truist Financial sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2022, closing a stake of 150,000 shares — an estimated $843K sold.

Truist Financial first reported a position in PRVB in Q4 2019 and held it in 9 quarters. The position peaked at $2.37M in Q4 2020. 113 funds tracked by Wall St. Rank hold PRVB as of Q1 2022.

Truist Financial reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Truist Financial sold 150,000 Provention Bio, Inc. Common Stock shares in Q1 2022, an estimated $843K.
Truist Financial first reported a position in Provention Bio, Inc. Common Stock in Q4 2019 and held it in 9 quarters.
Truist Financial's Provention Bio, Inc. Common Stock position peaked at $2.37M in Q4 2020.
113 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2022.

Based on Truist Financial's 13F filing for Q1 2022, filed 22 Apr 2022.